1 / 3

Rémission clinique après optimisation = 36,5 %

Rémission clinique après optimisation = 36,5 %. ECCO 2014 – D'après Roblin X et al., abstract DOP056, actualisé. (%). Rémission clinique après switch pour IFX = 31 %. ECCO 2014 – D'après Roblin X et al., abstract DOP056, actualisé. (%). Proposition d’algorithme de prise en charge.

judah-mclaughlin
Download Presentation

Rémission clinique après optimisation = 36,5 %

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Rémission clinique après optimisation = 36,5 % ECCO 2014 – D'après Roblin X et al., abstract DOP056, actualisé (%)

  2. Rémission clinique après switch pour IFX = 31 % ECCO 2014 – D'après Roblin X et al., abstract DOP056, actualisé (%)

  3. Proposition d’algorithme de prise en charge Rechute sous ADA (40 mg / 14 jours) ECCO 2014 – D'après Roblin X et al., abstract DOP056, actualisé TR-ADA basAA-ADA absents TR-ADA élevé TR-ADA bas AA-ADA présents Changement de classe thérapeutique Optimisation ADA (40 mg/sem.) Switch pour IFX

More Related